Skip to content

Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma

Pilot Study Evaluating Feasibility and Acceptability of Horse Therapy for Children, Adolescents and Young Adults in Remission From Medulloblastoma and Describing the Evolution of Their Physical and Psychological Characteristics

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05755295
Acronym
EQUI-HIPPO
Enrollment
15
Registered
2023-03-06
Start date
2023-04-03
Completion date
2026-03-01
Last updated
2023-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Keywords

hippotherapy, equitherapy

Brief summary

On average, each year in the former region, 60 new patients under the age of 18 are treated for a brain tumor, with an active post-treatment follow-up file of 350 patients. Because of the significant sequelae induced by the disease or the treatments, these patients will very often require rehabilitative care. The interest of involving the horse in the population of patients cured of a medulloblastoma but with important physical and psychological after-effects is to be able to combine a therapy using animal mediation (equitherapy) and a rehabilitation therapy based on the three-dimensional movement of the horse (hippotherapy).

Interventions

equitherapy and hippotherapy once a week during 16 weeks

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
10 Years to 26 Years
Healthy volunteers
No

Inclusion criteria

* complete remission of medulloblastoma and after 5 years of the end of treatment * living within 30 km away the riding center and/or less than 1 hour of transport * informed consent

Exclusion criteria

* Landsky score below 50% for minors until 16 years old and Karnofsky score below 50% for patients over 16 years * major under juridical protection

Design outcomes

Primary

MeasureTime frameDescription
number of sessions performed16 weeksnumber of sessions equitherapy and hippotherapy performed

Countries

France

Contacts

Primary ContactAnne-Isabelle BERTOZZI, MD
bertozzi.ai@chu-toulouse.fr05 34 55 86 83
Backup ContactFrançoise AURIOL, MD
auriol.f@chu-toulouse.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026